BTIG Issues a Buy Rating on Acutus Medical (AFIB)
BTIG Sticks to Its Buy Rating for Acutus Medical (AFIB)
BTIG Sticks to Their Buy Rating for Acutus Medical (AFIB)
BTIG Remains a Buy on Acutus Medical (AFIB)
BTIG Keeps Their Buy Rating on Acutus Medical (AFIB)
BTIG Sticks to Its Buy Rating for Acutus Medical (AFIB)
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Acutus Medical (AFIB)
Acutus Medical Is Maintained at Neutral by Goldman Sachs
Acutus Medical Price Target Raised to $1.50/Share From $1.00 by Goldman Sachs
Acutus Medical Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Acutus Medical (AFIB)
Acutus Medical (AFIB) Gets a Buy Rating from BTIG
Acutus Medical (AFIB) Gets a Buy Rating from BTIG
Acutus Medical Is Maintained at Buy by BTIG
Acutus Medical Price Target Cut to $1.50/Share From $2.00 by BTIG
Acutus Medical analyst ratings
BTIG Maintains Buy on Acutus Medical, Lowers Price Target to $1.5
BTIG Adjusts Acutus Medical's Price Target to $1.50 From $2, Reiterates Buy Rating
No Data
No Data